Summary of Viking Therapeutics (VKTX) Upcoming Developments
Oct 19, 2024 Viking Therapeutics (VKTX) is set to release its quarterly earnings after the market closes on Wednesday, October 23rd. Analysts predict an earnings per share (EPS) loss of ($0.24) for the quarter. While the earnings report is notable, a more significant catalyst for the stock is the upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding their drug candidate, VK2735.
VK2735: A Promising Treatment for Metabolic Disorders
- What is VK2735?
- VK2735 is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
- It is being developed for the potential treatment of various metabolic disorders, primarily obesity.
Clinical Trial Progress
- Phase 2 VENTURE Trial (Subcutaneous Administration)
- Completion Date: February 2024
- Results:
- Demonstrated an encouraging safety and tolerability profile.
- Showed positive signs of clinical benefit in treating obesity.
- Upcoming FDA Meeting
- Scheduled: Fourth quarter of 2024
- Purpose: An end-of-Phase 2 meeting to discuss the next steps in VK2735’s development based on the successful Phase 2 results.
- Oral Formulation Development
- Current Status: Evaluating an oral formulation in a Phase 1 trial.
- Future Plans:
- Based on positive Phase 1 results, Viking Therapeutics plans to initiate a Phase 2 obesity trial for the oral formulation in the fourth quarter of 2024.
Viking Therapeutics (VKTX) is set to release its quarterly earnings after the market closes on Wednesday, October 23rd. Analysts predict an earnings per share (EPS) loss of ($0.24) for the quarter. While the earnings report is notable, a more significant catalyst for the stock is the upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding their drug candidate, VK2735.
VK2735: A Promising Treatment for Metabolic Disorders
- What is VK2735?
- VK2735 is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
- It is being developed for the potential treatment of various metabolic disorders, primarily obesity.
Clinical Trial Progress
- Phase 2 VENTURE Trial (Subcutaneous Administration)
- Completion Date: February 2024
- Results:
- Demonstrated an encouraging safety and tolerability profile.
- Showed positive signs of clinical benefit in treating obesity.
- Upcoming FDA Meeting
- Scheduled: Fourth quarter of 2024
- Purpose: An end-of-Phase 2 meeting to discuss the next steps in VK2735’s development based on the successful Phase 2 results.
- Oral Formulation Development
- Current Status: Evaluating an oral formulation in a Phase 1 trial.
- Future Plans:
- Based on positive Phase 1 results, Viking Therapeutics plans to initiate a Phase 2 obesity trial for the oral formulation in the fourth quarter of 2024.
Viking Therapeutics (VKTX) is set to release its quarterly earnings after the market closes on Wednesday, October 23rd. Analysts predict an earnings per share (EPS) loss of ($0.24) for the quarter. While the earnings report is notable, a more significant catalyst for the stock is the upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding their drug candidate, VK2735.
VK2735: A Promising Treatment for Metabolic Disorders
- What is VK2735?
- VK2735 is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
- It is being developed for the potential treatment of various metabolic disorders, primarily obesity.
Clinical Trial Progress
- Phase 2 VENTURE Trial (Subcutaneous Administration)
- Completion Date: February 2024
- Results:
- Demonstrated an encouraging safety and tolerability profile.
- Showed positive signs of clinical benefit in treating obesity.
- Upcoming FDA Meeting
- Scheduled: Fourth quarter of 2024
- Purpose: An end-of-Phase 2 meeting to discuss the next steps in VK2735’s development based on the successful Phase 2 results.
- Oral Formulation Development
- Current Status: Evaluating an oral formulation in a Phase 1 trial.
- Future Plans:
- Based on positive Phase 1 results, Viking Therapeutics plans to initiate a Phase 2 obesity trial for the oral formulation in the fourth quarter of 2024.
Viking Therapeutics (VKTX) is set to release its quarterly earnings after the market closes on Wednesday, October 23rd. Analysts predict an earnings per share (EPS) loss of ($0.24) for the quarter. While the earnings report is notable, a more significant catalyst for the stock is the upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding their drug candidate, VK2735.
VK2735: A Promising Treatment for Metabolic Disorders
- What is VK2735?
- VK2735 is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
- It is being developed for the potential treatment of various metabolic disorders, primarily obesity.
Clinical Trial Progress
- Phase 2 VENTURE Trial (Subcutaneous Administration)
- Completion Date: February 2024
- Results:
- Demonstrated an encouraging safety and tolerability profile.
- Showed positive signs of clinical benefit in treating obesity.
- Upcoming FDA Meeting
- Scheduled: Fourth quarter of 2024
- Purpose: An end-of-Phase 2 meeting to discuss the next steps in VK2735’s development based on the successful Phase 2 results.
- Oral Formulation Development
- Current Status: Evaluating an oral formulation in a Phase 1 trial.
- Future Plans:
- Based on positive Phase 1 results, Viking Therapeutics plans to initiate a Phase 2 obesity trial for the oral formulation in the fourth quarter of 2024.